Pacira BioSciences, Inc. (PCRX)
Gross profit margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Gross profit | US$ in thousands | 700,966 | 490,309 | 467,528 | 401,278 | 303,502 |
| Revenue | US$ in thousands | 700,966 | 674,978 | 666,823 | 541,533 | 420,830 |
| Gross profit margin | 100.00% | 72.64% | 70.11% | 74.10% | 72.12% |
December 31, 2024 calculation
Gross profit margin = Gross profit ÷ Revenue
= $700,966K ÷ $700,966K
= 100.00%
The gross profit margin of Pacira BioSciences, Inc. has shown a generally positive trend over the years based on the data provided. It increased from 72.12% as of December 31, 2020, to 74.10% as of December 31, 2021, indicating improved efficiency in generating profits from its revenue. However, there was a slight decrease to 70.11% as of December 31, 2022, before rebounding to 72.64% as of December 31, 2023.
The most notable change occurred as of December 31, 2024, where the gross profit margin surged to 100.00%. This significant increase could be attributed to various factors such as an increase in sales revenue, cost control measures, or changes in the product mix. Further analysis would be needed to understand the specific reasons behind this sharp increase.
Overall, the upward trend in the gross profit margin signifies that Pacira BioSciences, Inc. has been effectively managing its cost of goods sold and enhancing its operational efficiency in recent years, which is a positive indicator of the company's financial health and profitability.
Peer comparison
Dec 31, 2024